

Nucleotide sequence of a cyclodextrin glucosyltransferase gene, *cgtA*, from *Bacillus licheniformis*

David E.Hill⁺, Robert Aldape[§] and J.David Rozzell^{*†}

Genetics Institute, 87 Cambridgepark Drive, Cambridge, MA 02140, USA

Submitted November 16, 1989

EMBL accession no. X15752

Cyclodextrin glucosyltransferases (CGTases), EC 2.4.1.19, convert starch into cyclic glucosyl oligosaccharides (cyclodextrins) having a hydrophilic surface and a hydrophobic core (1). Thus, cyclodextrins bind to and solubilize hydrophobic materials. Recently, a potential therapeutic benefit for cyclodextrins was demonstrated (2). Here we report the nucleotide sequence of a unique gene encoding a CGTase cloned from a strain of *Bacillus licheniformis* (3). The *B. licheniformis* gene, called *cgtA*, was cloned using procedures similar to those described (4) except the *B. licheniformis* library was prepared in a pUC19 derivative. *E. coli* transformants expressing a full length *cgtA* gene were initially identified on the basis of starch clearing ability as described (4). The *cgtA* clones were confirmed by measuring the conversion of 2% maltodextrin solution to cyclodextrin following growth in liquid culture. Cyclodextrins were identified and quantitated by HPLC using a cyclodextrin assay column purchased from Advanced Separation Technologies, Whippany, NJ; α and β cyclodextrins were the

principal products obtained. The *cgtA* gene, sequenced as described (5), is contained within a 2516 base pair Sau3A to SphI fragment encoding an open reading frame of 718 amino acids. The translated sequence exhibits 58% and 66% amino acid similarity, respectively, to the *B. macerans* CGTase (4) and either *Bacillus* sp. 1011 (6) or 38-2 (7). This similarity extends throughout the entire open reading frame except for the amino terminal leader sequences.

REFERENCES

1. Pulley,O.A. and French,D. (1961) *Biochem. Biophys. Res. Commun.* **5**, 11-15.
 2. Folkman,J. et al. (1989) *Science* **243**, 1490-1493.
 3. Aoki,H. et al (1987) Proceedings of the Meeting of the American Chemical Society.
 4. Takano,T. et al. (1986) *J. Bacteriol.* **166**, 1118-1122.
 5. Hill,D.E. et al. (1988) *Nucl. Acids Res.* **16**, 365-366.
 6. Kimura,K. et al. (1987) *J. Bacteriol.* **169**, 4399-4402.
 7. Kaneko,T. et al. (1988) *J. Gen. Microbiol.*
- ```

-209 GATCATAACTCGAGGGCCATGCTTTAACCCAAGCGGTTAGGACAACCCCGTAACCCCCAGGAGATACGGGGTTGGCGGTGTC
-119 GAAGGAGGAAGCTTTAACGCCAGAATGTCCTCGTACAGTTGAACCGCTGTATTGAGAGCGAGGTTAGTTGTTTGTGAAA
-29 ACTACTACATTGAGGGTGGATTAC ATGTTCAATGCCAACAGCGTCTCCCTGAGTACCGCTAACGCTCAGGCTACGGCTGCTGGC
 61 GGCAGTGCATTGCCCTTCTGCCGTTCCGATTATGCCATGCCGATACAGCTGCAACAAAGCAGAACTTCAGTACGGATGTC
151 ATCATCACTTGTACGGGATTTCTGGATGTTAACCCATCCAACACCCCTACGGGGCTGCCCTTGATGGCACGTGCAACCTG
241 AACGTTACTCGGGGGACTGGCAGGGATTGGTCAACAAACTGACAACATTCTAGTCACTGGGTGTCACGGCCCTCTGGATC
331 TCCCAGCTGCGAAATAATTCCGCTACATCAACTCAGGGTGTAAACATACGGCTATCGCTGATTTGGGCACGGGATTCAAG
421 AAGACCAATCGTATTCGAAACCATGACCGATTTCAGAATCTGTTAACCCGGCCATCGAAAGGCATCAAATCATATTGATTC
511 GCGCCAAACCATAGCTCCCTGCCATGGAAACCGATACTCCCTGCCAGAACGGAACTGTACGATAACGGCAACCTGGTGGCGGG
601 TACACCAATGATACCAACGGATACTTCAACACAAATGGCGCTCCGATTCTCCACTCTTGAGAATGCCATTACAAAACCTCTACGAT
691 CTGGCGCATGATCAACATAACAGCACGATCGCATACATTTCAAAAGACGCCATACGCTGGCTGAGATATGGCGTGGACGGCATT
781 CGTGTGATGCCGTCAGCACGATGCCCTCAGGGCTGCCAGAAAGACTGGATGTCATCTATGACACAGCCGTATTACCTTCGGC
871 GAATGGTTCTGGGATCTGTCGACCCGATCGGATAACACAGATTTCGCAATGAACTCTGGTATGAGTTTGCTTGTATCCGTTCAAT
961 TCGGCTGTCGCAACGTGTTCCGGATAACACCTCCACATGTCAGCGCTGGATTCCATGTCAGGGCTACGGCAGCAGATTACATCAG
1051 GTGAATGACCAACTCATTGACAACCATGATATGACCGGTTCAAAACCGACTGCTGTGAACAAACGCCGTCTGGAACAGGCTCTG
1141 GCCCTCACGCTGACCTACGCCGCTACCTGGCATATTGGTACCGAGCAGTACTGACTGGGAACGGCGACCCGGATAACCCGGGGC
1231 AAAATGCTCTCTCCAAATCGACTACAGCGTCAACGTCAGTCAAGCTGGCCTACGGCCTACGGCATTACTTCAGTGGAAAGACAT
1321 GTTCCACACAGCAGGCTGGATCAACATGATGTTATATGTTAGGCGCAAGTTGGCAAAGCGTTGGCGTGTGCGTTAACCGC
1411 AATCTCACGACGCCAACAGTATCAACTAATGCAATCGCTTCCATCAGGAACCTATACCGATGTCGCTGGCGTGTGAACCGA
1501 AACAAACATCACGCTCAGTGGAGGAATATTCTTCCACGGCTCGCTGCCAGGAGCTACCGCTGTGGCAATATACGCCAAGTGAACCG
1591 ACGCCAACATCACGCTACGGCTACGGGCTACGGGCTACGGGCTACGGGCTACGGGCTACGGGCTACGGGCTACGGGCTACGGG
1681 ACCGGTCACTCTGGTACACAGCGCTACGGGCTACGGGCTACGGGCTACGGGCTACGGGCTACGGGCTACGGGCTACGGGCTACGG
1771 GCGGGTGAATGCACTGGAAAGTAGCTGCCAATGGTGAACAGCAACGGCTATAACGATTCAACATTCCTAGGGGATCAGGTACGGTAC
1861 GTGCGGTTGTCATCAATAATGCCAACATGCCGCTGGGCGAGAATATCACCTGACAGGCAACGTGTCGCGACTCGGTAACGGACCA
1951 GGTGAGCTCCATTGGACGGCTTCATCAGGTCATCCACGCCAACCGGACTTGGTATATGACGCTAAGTGTGTTCCGGCCGGAAACAG
2041 CTGGAATTCAAGTCTTCAGAAAACAGCGCTACGGGCTACGGGCTACGGGCTACGGGCTACGGGCTACGGGCTACGGGCTACGGTACT
2131 GCCACAGTAACGATAAACTGGCAATAACTAGCCATAATCCATTAAATGAAGCCGGAGCAGCGCTTACAGCGTACACTCCGGTTTGA
2221 CGTTAACATGTTCTGGTTATCGGTAAGTCAATGGACTTCATGTTGCGCAGGATTCCGGTTGCGAGCAGCAGCATG

```

\* To whom correspondence should be addressed

Present address: <sup>†</sup>Applied BioTechnology, 80 Rogers Street, Cambridge, MA 02142, <sup>§</sup>American BioTechnologies, Inc., 359 Allston Street, Cambridge, MA 02139 and <sup>†</sup>Celgene Corp., 7 Powder Horn Drive, Warren, NJ 07060, USA